Geographical and temporal variations in clozapine prescription for schizophrenia

作者: Jimmi Nielsen , Rasmus Røge , Ole Schjerning , Holger J. Sørensen , David Taylor

DOI: 10.1016/J.EURONEURO.2012.03.003

关键词: Cross-sectional studyInternal medicineMedical prescriptionDiagnosis of schizophreniaClozapinePolypharmacySchizophreniaPsychiatryMedicineAntipsychoticCohort study

摘要: Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized. Trends the prescription of patients with ICD-10 F20.x schizophrenia were assessed using data from Danish national registers. Three substudies carried out: (i) an assessment differences patterns between 1996 and 2007 a cross-sectional design; (ii) comparison time first diagnosis to five-year cohort study, Cox regression model, two patient groups who diagnosed 2003; (iii) general psychiatric hospitals' use 2009. The results are as follows: percentage receiving rose 9.0% 10.1% (p<0.001). In same period, having treatment augmented another antipsychotic increased 43.1% 64.2%, p<0.001. Time until was longer for 2003 compared those (HR: 0.28 CI: 0.16-0.49). 2009 there significant variation administration one hospital other, percentages drug ranging 5.7% 16.8%, 10.2% mean. Although, 2007, increased.

参考文章(36)
Christos Pantelis, Timothy J R Lambert, Managing patients with "treatment-resistant" schizophrenia. The Medical Journal of Australia. ,vol. 178, ,(2003) , 10.5694/J.1326-5377.2003.TB05310.X
D. M. Taylor, L. Smith, S. H. Gee, J. Nielsen, Augmentation of clozapine with a second antipsychotic – a meta‐analysis Acta Psychiatrica Scandinavica. ,vol. 125, pp. 15- 24 ,(2012) , 10.1111/J.1600-0447.2011.01792.X
Ruth A. Dickson, William M. Glazer, Clozapine reduces violence and persistent aggression in schizophrenia The Journal of Clinical Psychiatry. ,vol. 59, pp. 8- 14 ,(1998)
Robert R. Conley, Deanna L. Kelly, Charles M. Richardson, Carol A. Tamminga, William T. Carpenter, The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. Journal of Clinical Psychopharmacology. ,vol. 23, pp. 668- 671 ,(2003) , 10.1097/01.JCP.0000096246.29231.73
Jimmi Nielsen, Søren Skadhede, Christoph U Correll, Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients Neuropsychopharmacology. ,vol. 35, pp. 1997- 2004 ,(2010) , 10.1038/NPP.2010.78
Chay-Hoon Tan, Naotaka Shinfuku, Kang Sim, Psychotropic prescription practices in east Asia: looking back and peering ahead. Current Opinion in Psychiatry. ,vol. 21, pp. 645- 650 ,(2008) , 10.1097/YCO.0B013E32830E6DC4
Michael J. Sernyak, Robert A. Rosenheck, Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006 Psychiatric Services. ,vol. 59, pp. 567- 569 ,(2008) , 10.1176/PS.2008.59.5.567
Troy A. Moore, Robert W. Buchanan, The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry. ,vol. 68, pp. 1751- 1762 ,(2007) , 10.4088/JCP.V68N1115
Patty M. M. Nooijen, Felix Carvalho, Robert J. Flanagan, Haematological toxicity of clozapine and some other drugs used in psychiatry Human Psychopharmacology-clinical and Experimental. ,vol. 26, pp. 112- 119 ,(2011) , 10.1002/HUP.1181
Jimmi Nielsen, Claus Graff, Jørgen K. Kanters, Egon Toft, David Taylor, Jonathan M. Meyer, Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. ,vol. 25, pp. 473- 490 ,(2011) , 10.2165/11587800-000000000-00000